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HLA Antigens in Primary Sclerosing Cholangitis 
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S. Iwatsuki, T.E. Starzl, and Y. Iwaki 
PRIMARY sclerosing cholangitis (PSC) is an uncom-
mon liver disease and its etiology is unclear. How-
ever, PSC was shown to be associated with certain HLA 
antigens, such as HLA AI, B8, or DR3, suggesting the 
presence of underlying abnormal autoimmunity, although 
the number of patients in the earlier studies was rather 
Iimited. I- 3 In this study, we analyzed HLA antigens in a 
relatively large number of patients with PSC. 
MATERIALS AND METHODS 
The subjects of this study were 133 North American Caucasian 
PSC patients who received orthotopic liver transplantation at the 
University Pittsburgh Medical Center (Pittsburgh, Pal from De-
cl:mber 1981 to May 1991. Of those, 77 patients had ulcerative 
colitis (UC), 9 had Crohn's disease, and 10 had hepatobiliary 
carcmoma in addition to PSC. 
HLA typing was performed by the standard National Institutes 
of Health method using the best commercially available HLA 
typing trays. 
Since the HLA typing had been done over the 100year period, 
the patients were divided into 2 groups according to when their 
HLA typing was performed (group no. 1: 78 patients from 
December 1981 to December 1988 and group no. 2: 55 patients 
from January 1989 to May 1991). 
HLA phenotype frequency of 1.145 North American Cauca-
sians served as control and chi-square test was used for statistical 
analysis. 
RESULTS 
In both groups no. 1 and 2, the phenotype frequencies of 
HLA-B8, DR3. and DR6 in patients with PSC were 
significantly higher than those observed in control (Table 
1). In addition, the significance was consistent regardless 
of the presence of UC, Crohn's disease, or hepatobiliary 
carcinoma. 
There was an increased frequency of HLA-AI and a 
decreased frequency of HLA-DRI in patients from group 
no. 1; however, there were no such trends in group no. 2. 
Similarly, higher frequencies of A24 and A26 and a de-
creased frequency of DR7 were observed in patients of 
group no. 2 but not in group no. 1. 
DISCUSSION 
DR3 or DR6 antigens were highly associated with a 
presence of autoimmune diseases such as myasthenia 
gravis, Sjogren's syndrome, and insulin-dependent diabe-
tes mellitus. From this study, it appeared that PSC seemed 
to be associated with certain HLA phenotypes, particu-
larly, B8, DR3, and DR6, suggesting that some autoim-
mune disorder could be present in patients with PSC. 
Table 1. HLA Phenotype Frequenclea In Patients WIth Primary 
Sclerosing Cholangitis 
PrImary Sclerosing Cholangitis 
1981-1988 1989-1991 
HLA Percent of Percent of Percent of 
AnIgen Controls patIenII p-va. patIenII P-va. 
Al 25.7 42.3 . P< .01 36.7 NS 
A2 46.6 44.9 NS 38.2 NS 
A3 26.0 23.1 NS 21.0 NS 
A24 12.8 14.1 NS 23.7 P< .05 
A26 7.2 5.1 NS 16.4 P< .05 
(n = 1,029) (n = 78) (n = 55) 
B7 18.7 21.8 NS 20.0 NS 
B8 17.1 43.6 P< .001 36.7 P< .001 
639 3.6 1.3 NS 3.6 NS 
B44 26.1 16.7 NS 16.4 NS 
(n = 1,029) (n = 78) (n = 55) 
DR1 20.0 8.0 P< .05 11.8 NS 
DR2 25.3 21.3 NS 27.5 NS 
DR3 22.2 40.0 P< .05 39.2 P< .01 
DR4 27.3 17.3 NS 15.7 NS 
DRS 19.4 18.7 NS 17.6 NS 
DR6 7.2 40.0 P< .001 43.1 P< .001 
DR7 23.6 20.0 NS 9.8 P< .05 
DRB 5.3 1.3 NS 2.0 NS 
DR9 3.0 NA 0.0 NS 
DR10 1.2 NA 2.0 NS 
Blank 32.0 25.5 
DR3or6 29.3 69.3 P< .001 76.5 P< .001 
(n=1,145) (n = 75) (n = 51) 
It is possible that DR3 or DR6 alleles might be highly 
disease restricted; however, the analysis of class II haplo-
type by cellular, biochemical, and molecular techniques 
has revealed extensive genetic heterogeneity within sero-
logically defined DR types. Thus, the association with PSC 
cannot simply be explained by the direct linkage with DR3 
or DR6 gene products. The epitopes of DR3 as well as DR6 
are expressed on DR131 molecules. Such DR antigens have 
strong linkage disequilibrium with other alleles, particu-
larly DRI33 or DRI34 legions. In fact, approximately half of 
the DR3 found was reported to have DR52a, which is 
expressed on DRI33 molecule, as was DR6.4 DR52b is also 
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found in about half of DRl and DR6.4 Thus, it is possible 
that class II antigens expressed on DRI33 molecules could 
be associated with PSC. In fact, Prochazka et ae reported 
tbat all patients with PSC had DR52a. although our pre-
liminary study revealed that only two thirds of patients 
with PSC had DR52a. Nevertheless. it is possible that PSC 
could simply be associated with DRI33 class II antigen. and 
an increased frequency ofB8 could be simply explained by 
a strong linkage disequilibrium between such DRI33 class 
II antigens and B8. 
In some autoimmune disorders. such as myasthenia 
gravis (which is also associated with DRJ) it was reported 
that a certain peptide binds readily with myasthenia gravis-
associated class II prodUcts, which would trigger an acti-
vation oflymphocytes. resulting in autoimmune disorder.5 
If there is an underlying autoimmune disorder in PSC. it 
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would be probable that lymphocyte activation must be 
triggered by some undefined PSC-associated peptide 
which would specifically bind to DR3 or DR6. or DRt3) 
gene products. 
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